Skip to main content
ACET
NASDAQ Life Sciences

Adicet Q3: $100.9M Cash Into 2H 2027, Pivotal Lupus Study Starting, FDA Meeting in 4Q

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.95
Mkt Cap
$27.336M
52W Low
$2.87
52W High
$11.374
52W Position info
2.8% above low
Off High info
74% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

ACET is trading near its 52-week low of $2.87 (2.8% above the low) on elevated volume (2.0× avg).

Summary

Adicet reported a narrower Q3 loss ($18.9M vs $26.9M) and $100.9M in cash it says funds operations into 2H 2027, while starting a pivotal lupus nephritis study and planning a 4Q 2026 FDA meeting on expanding it to non-renal lupus.


Key Events · Earnings and Guidance · ACET

  • Q3 Loss Narrows on Lower Spend

    Net loss was $18.9M, or $1.76 per basic and diluted share, versus $26.9M ($4.72 per share) in Q3 2025; R&D fell to $15.6M from $22.9M and G&A to $4.2M from $5.1M.

  • Cash Runway Into Second Half 2027

    Cash, cash equivalents and short-term investments totaled $100.9M at September 30, 2026, down from $158.5M at December 31, 2025; the company expects funding into 2H 2027.

  • Pivotal Lupus Nephritis Study Starting

    Start-up activities are underway for a single-arm pivotal study in lupus nephritis, with complete renal response at 12 months as the primary endpoint and a double-digit patient target.

  • FDA Meeting Set for Fourth Quarter

    The company plans 4Q/2026 FDA engagement on expanding the pivotal program to lupus patients without nephritis, with a regulatory update and 12-month data from ~22 patients expected in 1Q/2027.


Analysis · ACET · Life Sciences

The quarter itself is a cost story: R&D fell to $15.6M from $22.9M and G&A to $4.2M from $5.1M, cutting the net loss to $18.9M from $26.9M a year ago. More important is what the cash buys — $100.9M funds operations into the second half of 2027, past the 1Q/2027 regulatory update and 12-month prula-cel follow-up and the 2Q/2027 systemic sclerosis readout. The company has begun start-up on a single-arm pivotal lupus nephritis study and will meet the FDA in 4Q/2026 about extending that pivotal program to lupus patients without nephritis, a materially larger label if granted. With the stock near its 52-week low, the risk is that the pivotal study and the in vivo CAR-T buildout consume the runway before a partnering or financing decision is forced.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACET was trading at $2.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.3M. The 52-week trading range was $2.87 to $11.37. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACET - Latest Insights

ACET
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.95
Real-time Price: $2.16 info
Change: -$0.790 (-27%) info
Market Cap: $20.315M info
ACET
Sep 28, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.96
Real-time Price: $2.16 info
Change: -$6.80 (-76%) info
Market Cap: $20.315M info
ACET
Sep 28, 2026, 6:45 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $9.99
Real-time Price: $2.16 info
Change: -$7.83 (-78%) info
Market Cap: $20.315M info
ACET
Sep 01, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.72
Real-time Price: $2.16 info
Change: -$6.56 (-75%) info
Market Cap: $20.315M info
ACET
Aug 27, 2026, 4:00 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.97
Real-time Price: $2.16 info
Change: -$6.81 (-76%) info
Market Cap: $20.315M info